DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Pharmaceutical Industry Business Outlook and Procurement Report H1 2016" report to their offering.
The "Pharmaceutical Industry Business Outlook and Procurement Report H1 2016" examines executives' opinion on business outlook and procurement activities over April-September 2016. It also highlights key business priorities, supplier price variations, changes in capital expenditure, and the key equipment and drug categories with the highest revenue contribution to the pharmaceutical industry. Additionally, it provides information categorized by region and company type.
The key priorities forecast in the business structure for global pharmaceutical industry executives in H1 2016 (April-September 2016) are new product development and improving operational efficiency. China, India, and Brazil are the leading emerging markets that are expected to offer the most opportunities for global pharmaceutical industry growth in H1 2016.
Market uncertainty and rising competition are the immediate business concerns for global pharmaceutical industry executives. The gradual slowdown and restructuring of economic activity in China and tightening of the monetary policy in the US are creating a major concern for the pharmaceutical industry. Packaging equipment is expected to offer significant growth opportunities within the pharmaceutical industry in Asia-Pacific.
Avoidance of counterfeiting and provision of longer shelf life are identified as the key drivers for pharmaceutical packaging companies to witness significant business opportunities within the Asia-Pacific region.
Key Findings
- The top three key priorities for H1 2016 (April-September 2016) as identified by respondents include new product development, improving operational efficiency, and expansion in current market
- Developed markets such as the US, the UK, and Japan are identified as important regions for growth over the next six months by pharmaceutical respondents
- New product development and IT infrastructure development will record a significant increase or notable increase in capital expenditure over the next six months
- Overall, 52% of executives operating in Europe assigned high preference for outright purchase of pharmaceutical equipment
- In Asia-Pacific, executives forecast packaging equipment and process equipment will offer significant revenue growth opportunities within the pharmaceutical industry
Key Topics Covered:
1. Introduction
- Definitions
- Methodology and sample size
- Respondent profile
2. Global Business Outlook in H1 2016
- Strategic business priorities
- Emerging markets with significant growth potential
- Growth potential for developed markets
- Mergers and acquisition
- Leading business concerns
- Capital expenditure projections
3. Procurement Budget, Expenditure Outlook, and High-yield Categories
- Purchase preferences for pharmaceutical equipment
- Average expenditure per purchase
- Distribution of procurement budget between capital and operating expenditure
- Change in procurement budget expenditure
- Variation in pharmaceutical equipment budget from 2015-2016 to 2016-2017
- Highest revenue contributing regions for pharmaceutical equipment's market, 2016-2020
- Leading drug categories, 2016-2020
- Top most pharmaceutical equipment types, 2016-2020
4. Appendix
Companies Mentioned
- Albany Molecular Research Inc. (AMRI)
- Aurobindo Pharma
- Cipla
- DiCE Molecules
- Eagle Pharmaceuticals
- Exelan Pharmaceuticals Inc.
- Humanwell Healthcare Group and PuraCap Pharmaceutical
- InvaGen Pharmaceuticals Inc
- Johnson & Johnson
- Juno Therapeutics
- Mankind Pharma
- Meda Aktiebolag
- Mylan
- Sanofi S.A.
- Tesaro Inc.
- WuXi AppTec
For more information visit http://www.researchandmarkets.com/research/qvk39q/pharmaceutical
